BioWorld

April 14, 2006

View Archived Issues

MGI Submits NDA Seeking FDA Clearance For Saforis

Read More

New Channel Mutations Seen As Neurodegeneration Cause

Read More

Start-Up Cempra Brings Aboard Optimer's Antibacterial Program

Read More

Other News To Note

Read More

Appointments And Advancements

Read More

Gilead Invests $25M In Corus While Retaining Buyout Option

Gilead Sciences Inc. is putting $25 million into Corus Pharma Inc., and has an option to buy the rest of the respiratory disease-focused firm down the road. (BioWorld Today) Read More